AbbVie Inc. Exchange Rate Adjustment

Exchange Rate Adjustment of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Exchange Rate Adjustment growth rates and interactive chart.


Highlights and Quick Summary

  • Exchange Rate Adjustment for the quarter ending September 29, 2019 was $-16 Million (a -300.0% decrease compared to previous quarter)
  • Year-over-year quarterly Exchange Rate Adjustment increased by 60.0%
  • Annual Exchange Rate Adjustment for 2018 was $-39 Million (a -234.48% decrease from previous year)
  • Annual Exchange Rate Adjustment for 2017 was $29 Million (a -108.58% decrease from previous year)
  • Annual Exchange Rate Adjustment for 2016 was $-338 Million (a 12.67% increase from previous year)
  • Twelve month Exchange Rate Adjustment ending September 29, 2019 was $-17 Million (a 70.0% increase compared to previous quarter)
  • Twelve month trailing Exchange Rate Adjustment decreased by -56.41% year-over-year
Trailing Exchange Rate Adjustment for the last four month:
29 Sep '19 29 Jun '19 30 Mar '19 30 Dec '18
$-17 Million $-10 Million $-53 Million $-39 Million
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Exchange Rate Adjustment of AbbVie Inc.

Most recent Exchange Rate Adjustmentof ABBV including historical data for past 10 years.

Interactive Chart of Exchange Rate Adjustment of AbbVie Inc.

AbbVie Inc. Exchange Rate Adjustment for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $-16.0 $8.0 $1.0
2018 $-10.0 $-9.0 $-35.0 $15.0 $-39.0
2017 $0.0 $6.0 $7.0 $16.0 $29.0
2016 $-38.0 $7.0 $-13.0 $-294.0 $-338.0
2015 $-59.0 $-21.0 $4.0 $-224.0 $-300.0
2014 $-425.0 $-150.0 $3.0 $-5.0 $-577.0
2013 $-1.0 $11.0 $-6.0 $-14.0 $-10.0
2012 $16.0 $16.0
2011 $0.0 $0.0
2010 $0.0
2009 $0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.